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Background Chemo- and radiotherapy for breast cancer (BC) can lead to cardiotoxicity even years after the initial treatment.
The pathophysiology behind these late cardiac effects is poorly understood. Therefore, we studied a large panel of
biomarkers from different pathophysiological domains in long-term BC survivors, and compared these to matched
controls.
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Methods
and results
In total 91 biomarkers were measured in 688 subjects: 342 BC survivors stratified either to treatment with
chemotherapy ± radiotherapy (n = 170) or radiotherapy alone (n = 172) and matched controls. Mean age was
59± 9 years and 65± 8 years for women treated with chemotherapy ± radiotherapy and radiotherapy alone,
respectively, with a mean time since treatment of 11± 5.5 years. No biomarkers were differentially expressed in
survivors treated with radiotherapy alone vs. controls (P for all >0.1). In sharp contrast, a total of 19 biomarkers
were elevated, relative to controls, in BC survivors treated with chemotherapy ± radiotherapy after correction
for multiple comparisons (P <0.05 for all). Network analysis revealed upregulation of pathways relating to collagen
degradation and activation of matrix metalloproteinases. Furthermore, several inflammatory biomarkers including
growth differentiation factor 15, monocyte chemoattractant protein 1, chemokine (C-X-C motif) ligand 16, tumour
necrosis factor super family member 13b and proprotein convertase subtilisin/kexin type 9, elevated in survivors
treated with chemotherapy, showed an independent association with lower left ventricular ejection fraction.
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Conclusion Breast cancer survivors treated with chemotherapy ± radiotherapy show a distinct biomarker profile associated with
mild cardiac dysfunction even 10 years after treatment. These results suggest that an ongoing pro-inflammatory state
and activation of matrix metalloproteinases following initial treatment with chemotherapy might play a role in the
observed cardiac dysfunction in late BC survivors.
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Introduction
Worldwide, breast cancer (BC) is the most common cancer in
women. Improved oncological treatment has reduced mortality in
patients with BC.1,2 An unfortunate complication of chemotherapy
and/or radiotherapy is the development of cardiotoxicity leading to
cardiovascular disease (CVD).1–4
Yet, the pathophysiological mechanisms leading to cardiotox-
icity are poorly understood.3 The effects of oncological treat-
ment depend on the treatment modality used (e.g. radiotherapy,
chemotherapy, or both) and dosage received. In the acute phase,
treatment with chemotherapy may lead to necrosis, apoptosis and
cell loss.3 Agents like doxorubicin can cause oxidative stress by
increasing the production of reactive oxygen species.5–7 Further-
more, treatment can cause damage to endothelial cells and subse-
quent inflammation, leading to cardiac fibrosis.7
Biomarkers can be useful to study possible pathophysiologi-
cal changes in disease and following treatment.8–10 Several stud-
ies have shown a predictive association of biomarkers with
cardiotoxicity during and right after treatment with chemo-
and/or radiotherapy.11,12 A recent study13 found that inflamma-
tory biomarkers were increased in BC survivors >4 years after
treatment; however, this study was limited by lack of age-matched
controls and a low number of biomarkers included. Therefore, we
studied biomarker profiles in long-term BC survivors stratified by




This study included BC survivors and age and PCP matched con-
trols from the Breast cancer Long-term OutCome (BLOC) study, of
which design and results have been published previously.14 Between
2013 and 2016, the BLOC study enrolled 350 female early BC sur-
vivors, diagnosed ≥5 years ago who were cancer-free since treat-
ment, and 350 age and PCP matched control women never diag-
nosed with cancer. Of the 350 survivors of early BC, 175 patients
were post-operatively treated with only radiotherapy and 175 with
chemotherapy ± radiotherapy. Biomarker measurements were avail-
able in 342 survivors and 346 controls (total 688 participants) of the
original study cohort. The medical ethics committee of the University
Medical Center Groningen (UMCG) approved this study and all par-
ticipants gave written informed consent. The study was registered on
clinicaltrials.gov (NCT01904331). This study was performed in accor-
dance with the Declaration of Helsinki.
Study assessments and biomarker
measurements
Data on previous medical history and medication use were collected
from electronic patient files from the PCP based on the International
Classification of Primary Care (ICPC) codes for cardiovascular risk
factors and CVD at time of cross-sectional measurement and at a
time of anti-cancer treatment. Additional information such as smok-
ing history, alcohol consumption and a family history of CVD were



















































































.. participants underwent a physical examination at inclusion, determin-
ing blood pressure, body mass index (BMI) and waist circumference.
Renal function was assessed by calculation of estimated glomerular fil-
tration rate from serum creatinine. Radiotherapy in the Netherlands
consists of Linac-based photon tangential fields up to a dose of 50 Gy
with or without a boost. In addition, two-dimensional echocardiogra-
phy was performed at the UMCG by experienced blinded staff using
the biplane Simpson’s method according to the guidelines of the Amer-
ican Society of Echocardiography/European Association of Cardiovas-
cular Imaging.15 Blood samples were drawn before echocardiographic
assessment and directly analysed for lipid spectrum, renal function and
glucose. Additionally, lithium-heparin plasma samples were immediately
stored at −80∘ for biomarker assessment.
Biomarker analyses were performed at Olink Bioscience (Uppsala,
Sweden) using the Olink Proseek Olink Proseek® Multiplex CVD
III I96x96 kit, which measures 92 cardiovascular-related proteins
simultaneously in 1 μL plasma samples.16 The kit is based on a prox-
imity extension assay technology, where 92 oligonucleotide-labelled
antibody pairs are allowed to bind to their respective targets.
This technique has a major advantage over conventional multi-
plex assays, in that only correctly matched antibody pairs provide
a signal, giving a very high specificity. Amplicons were quantified
using a Fluidigm BioMark™ HD real-time polymerase chain reac-
tion platform, which provides normalized protein expression data,
where a high protein value corresponds to a high protein con-
centration. The Olink assay uses four built-in internal controls,
providing technical control for each individual sample. In addition,
eight external controls including two pooled plasma samples are
used to calculate intra- and interpolate coefficients of variation for
each assay. An overview of disease domains of biomarkers involved
is provided in online supplementary Table S1. Intra- and inter-assay
coefficients of variation are reported in online supplementary
Table S2.
Statistical analyses
Baseline characteristics were compared between patients previously
treated with chemotherapy ±/or radiotherapy alone and their respec-
tive matched controls using Students’ t-test, the Mann–Whitney U
test or the Chi-square test depending on the nature and distribu-
tion of the variable. Biomarker profiles between BC survivors and
respective controls were compared using logistic regression analy-
ses stratified to treatment modality, correcting for age, BMI, renal
function and a diagnosis of CVD in multivariable analyses. Sensi-
tivity analysis was performed by repeating our analyses in subjects
who received chemotherapy alone compared to matched controls.
To correct for multiple comparisons, we used a false discovery rate
of 0.1 using the Benjamini–Hochberg method. We performed sen-
sitivity analyses restricting our analyses only to survivors with a
T-classification of ≥2. We created a general network of human physical
protein–protein interaction (PPI) (HsapiensPPI), consisting of 17 625
unique nodes with 330 157 interactions between them based on data
from BIND,17 BioGRID,18 DIP,19 HPRD,20 IntAct21 and PDZBase.22
Context-specific networks were constructed by selecting nodes and
interactions that occur only between members from the protein list
being investigated (N0 networks) and/or by selecting nodes that indi-
rectly interact, one-neighbour-away, with members of the list (N1
networks). Physical cohesiveness of context-specific networks were
assigned using the Physical Interaction Enrichment procedure that cor-
rects for biased enrichment, in general PPI networks, of proteins that
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics
Radiotherapy Chemotherapy ± radiotherapy
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Control Treated P-value Control Treated P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients, n 172 170 174 172
Demographics
Age (years) 64.8 (6.9) 65.2 (7.5) 0.59 59.6 (9.1) 59.3 (9.2) 0.71
BMI (kg/m2) 26.9 (4.8) 26.9 (5.5) 0.97 25.9 (4.3) 26.2 (4.0) 0.52
Time since therapy (years) – 11.6 (5.2) – 11.3 (5.5)
eGFR (mL/min/1.73 m2) 74.1 (13.7) 74.4 (17.5) 0.84 75.8 (13.3) 74.3 (14.6) 0.3
Medical history, n (%)
Hypertension 61 (35.5) 60 (35.3) 0.97 42 (24.1) 46 (26.7) 0.58
Diabetes 8 (4.7) 20 (11.8) 0.016 7 (4.0) 9 (5.2) 0.59
Dyslipidaemia 30 (17.4) 32 (18.8) 0.74 28 (16.1) 21 (12.2) 0.3
Artificial heart valve 2 (1.2) 1 (0.6) 0.57 0 (0.0) 1 (0.6) 0.31
Cardiovascular disease 6 (3.5) 14 (8.2) 0.061 8 (4.6) 15 (8.7) 0.12
Heart failure 2 (1.2) 0 (0.0) 0.16 1 (0.6) 1 (0.6) 0.99
Atrial fibrillation 4 (2.3 6 (3.5) 0.51 1 (0.6) 4 (2.3) 0.17
Medication, n (%)
ACE inhibitors 23 (13.4) 31 (18.2) 0.22 19 (10.9) 33 (19.2) 0.031
Beta-blockers 19 (11.0) 32 (18.8) 0.044 14 (8.0) 21 (12.2) 0.2
CCB 13 (7.6) 7 (4.1) 0.18 9 (5.2) 7 (4.1) 0.63
Diuretics 26 (15.1) 18 (10.6) 0.21 12 (6.9) 13 (7.6) 0.81
Anticoagulants 11 (6.4) 18 (10.6) 0.16 8 (4.6) 19 (11.0) 0.025
Antiplatelet therapy 5 (2.9) 13 (7.6) 0.05 6 (3.4) 16 (9.3) 0.026
Statins 26 (15.1) 30 (17.6) 0.53 13 (7.5) 23 (13.4) 0.072
Laboratory
HDL-cholesterol (mmol/L) 1.8 (0.5) 1.7 (0.4) 0.038 1.8 (0.5) 1.7 (0.5) 0.77
Total cholesterol (mmol/L) 5.7 (1.0) 5.6 (1.1) 0.73 5.6 (1.2) 5.5 (1.1) 0.9
Triglycerides (mmol/L) 1.2 (0.7) 1.4 (0.8) 0.13 1.3 (0.7) 1.3 (0.8) 0.43
LDL-cholesterol (mmol/L) 3.5 (1.0) 3.5 (1.1) 0.7 3.5 (1.1) 3.4 (1.0) 0.6
Glucose (mmol/L) 5.6 (1.0) 5.9 (1.7) 0.063 5.5 (1.0) 5.5 (1.0) 0.73
C-reactive protein (mg/L) 1.4 [0.8–3.0] 1.7 [0.9–4.0] 0.19 1.4 [0.8–3.0] 1.9 [1.0–4.0] 0.017
NT-proBNP (pg/mL) 82.0 [50.5–140.5] 97.0 [51.0–160.0] 0.15 71.5 [46.0–125.0] 97.5 [58.0–148.5] 0.002
Echocardiography
LVEF (%) 59.0 [57.5–61.5] 58.0 [55.0–62.0] 0.11 59.0 [57.0–62.0] 57.5 [55.0–60.0] <0.001
Systolic dysfunction (LVEF <54%) 13 (7.7) 27 (16.3) 0.016 13 (7.5) 25 (15.0) 0.029
E′ septal (cm/s) 7 [6–9] 7 [6–9] 0.73 8 [7–10] 8 [6–9] 0.31
E′ lateral (cm/s) 10 [8–11] 9 [7–11] 0.416 10.7 [8.8–12.4] 10.4 [7.9–12.4] 0.23
E/e′ 7.5 [6.4–9.0] 7.6 [6.6–9.1] 0.38 7.2 [6.1–8.2] 7.0 [5.9–8.1] 0.29
Prior treatment
Time since therapy (years) – 11.6 (5.2) – 11.3 (5.5)
Anti-hormonal therapy 38 (22) 108 (63)
Cumulative anthracycline doses (mg/mL) – 238 [228–240]
Trastuzumab 0 (0) 13 (9)
Radiotherapy (%) 100 69
LV mean dose (Gy) 2 [0.6–6.5] 1.9 [0.6–6.0]
Values are given as mean ± standard deviation, n (%), or median [interquartile range].
ACE, angiotensin-converting enzyme; BMI, body mass index; CCB, calcium channel blocker; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; LV, left ventricular; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SD, standard deviation.
are often studied.23 Analysis of PPIs was performed and plotted using
Cytoscape version 3.7.0, where the node size corresponds to the
betweenness centrality. A larger node size, the more connected the
node is in the network. We used the ClueGO app in Cytoscape to
investigate over-represented biological pathways using data from the








. association of biomarkers with left ventricular ejection fraction (LVEF).
The association of biomarkers with LVEF was tested using multivariable
linear regression analysis, correcting for age, renal function, BMI, his-
tory of or current CVD, treatment with anti-hormonal therapy and
treatment with radiotherapy. All analyses were performed using R, ver-
sion 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).
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Figure 1 (A) Heatmap depicting -log10 (P-value) of biomarker associations with the chemotherapy/radiotherapy and radiotherapy group
vs. age- and sex-matched controls. Red signifies P< 0.05 while blue signifies P> 0.05. (B) Forest plot depicting multivariable odds ratios for
biomarker levels in survivors treated with chemotherapy ± radiotherapy vs. controls. CI, confidence interval.
Results
Baseline characteristics
Breast cancer survivors treated with radiotherapy alone had a
slightly higher prevalence of diabetes (12% vs. 5%, P = 0.016) com-
pared to controls and were more often on beta-blockers (19% vs.
11%, P = 0.044) (Table 1). BC survivors treated with chemotherapy
± radiotherapy more often used angiotensin-converting enzyme
inhibitors (19% vs. 11%, P = 0.03), anticoagulants (11% vs. 5%,
P = 0.025) and antiplatelet therapy (9% vs. 3%, P = 0.026). Sur-
vivors treated with chemotherapy ± radiotherapy had a mean age
of 59 years ± 9 years, survivors treated with radiotherapy alone had
a mean age of 65 ± 8 years. In the group treated with chemother-
apy, 69% received additional radiotherapy. The median cumulative
anthracycline doses for the chemotherapy was 238 (interquartile
range 228–240) mg/m2. A total of 108 (63%) survivors treated
with chemotherapy ± radiotherapy were also treated with
anti-hormonal therapy, while 38 (22%) of survivors treated
with radiotherapy were also treated with anti-hormonal therapy
(Table 1). Mean follow-up time since treatment was 11± 5.5 years.
Time since treatment did not differ between survivors treated
with radiotherapy alone (11± 5 years) and those treated
with chemotherapy ± radiotherapy (11± 6 years, P = 0.453).
N-terminal pro-B-type natriuretic peptide (NT-proBNP) and






































.. previously treated with chemotherapy ± radiotherapy compared
to controls.
Biomarkers and pathways
No significant differences were found in biomarker levels
between BC survivors treated with radiotherapy alone vs.
controls (Figure 1A). In sharp contrast, 19 biomarkers had sig-
nificantly higher levels in survivors treated with chemotherapy
± radiotherapy compared to controls (Figure 1A). After multi-
variable adjustment for age, BMI, renal function and a diagnosis
of CVD, all these 19 biomarkers remained significantly higher in
survivors treated with chemotherapy ± radiotherapy compared
to controls (Figure 1B). Further correction for LVEF did not affect
these results (P remained <0.05 for all). Biomarker levels were
not associated with time since treatment (P> 0.1 for all). When
restricting our analyses only to survivors with a T-classification of
≥2, similar results were observed (online supplementary Table S3).
No association between the biomarkers and received radiation
dose was observed (P for all >0.2). No association between any of
the differentially regulated biomarkers and received anthracycline
dose was observed.
To provide biological context to the proteins found, we per-
formed network analysis and pathway over-representation anal-
ysis (Figure 2). We observed that galectin-3, osteopontin, matrix
metalloproteinase (MMP) 2, MMP-3 and epidermal growth factor
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Results from network analysis showing protein–protein interactions for empirically identified markers (orange), predicted markers
(blue) and associated pathways (green). ACP5, acid phosphatase 5, Tartrate Resistant; ALCAM, activated leukocyte cell adhesion molecule;
CCL2, chemokine (C-C motif) ligand 2; CCL15, chemokine (C-C motif) ligand 15; CHI3L1, chitinase-3-like protein 1; EGFR, epidermal growth
factor receptor; GRN, granulin; HSPG2, heparan sulfate proteoglycan 2; LDLR, low-density lipoprotein receptor; LGALS3, galectin-3; MMP2,
matrix metalloproteinase 2; MMP3, matrix metalloproteinase 3; PCSK9, proprotein convertase subtilisin/kexin type 9; PDGFA, platelet-derived
growth factor subunit A; SPP1, secreted phosphoprotein 1; TIMP4, tissue inhibitor of metalloproteinase 4.
receptor were important hubs (larger nodes) within the network.
Following pathway over-representation analysis, we observed that
pathways relating to collagen degradation, activation of MMPs and
collagen catabolic processes were significantly over-represented in
survivors treated with chemotherapy ± radiotherapy (Figure 2).
To exclude the possibility that differentially regulated biomark-
ers in the chemotherapy ± radiotherapy group were the conse-
quence of the higher prevalence of current and past cardiovascu-
lar events, we performed additional sensitivity analyses restrict-
ing our analyses to BC survivors without any history of CVD,
which did not affect our findings. Secondly, to exclude the pos-
sibility that the differentially regulated biomarkers were the con-


















.. performed analyses restricting to BC survivors only treated with
chemotherapy, which showed similar results (online supplementary
Table S4).
Association with left ventricular ejection
fraction
From the biomarkers that were significantly up-regulated in sur-
vivors treated with chemotherapy ± radiotherapy, higher levels of
tumour necrosis factor super family member 13b (TNFSF13B),
monocyte chemoattractant protein 1, growth differentiation fac-
tor 15, chemokine (C-X-C motif) ligand 16, peptidase inhibitor
3, insulin growth factor binding protein 7, proprotein convertase
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Association of biomarkers with left
ventricular ejection fraction after correction for age,
renal function, body mass index, history of or current
cardiovascular disease, treatment with anti-hormonal
therapy and treatment with radiotherapy in survivors
treated with chemotherapy and/or radiotherapy
Biomarker Standardized beta P-value




















CNTN1, contactin-1; CTSZ, cathepsin Z; CXCL16, Chemokine (C-X-C motif)
ligand 16; FABP4, fatty acid binding protein 4; Gal3, galectin-3; Gal4, galectin-4;
GDF15, growth differentiation factor 15; KLK, kallikrein-6; IGFBP7, insulin-like
growth factor-binding protein 7; MCP1, monocyte chemoattractant protein 1;
OPN, osteopontin; PCSK9, proprotein convertase subtilisin/kexin type 9; PI3,
peptidase inhibitor 3; PLC, perlecan; RARRES2, retinoic acid receptor responder
protein 2; SCGB3A2, secretoglobin family 3A member 2; TFPI, tissue factor
pathway inhibitor; TIMP4, tissue inhibitor of metalloproteinase 4; TNFSF13B,
tumour necrosis factor super family member 13b.
subtilisin/kexin type 9 (PCSK9), osteopontin and perlecan showed
a significant association (P for all <0.05) with lower LVEF in the
group treated with chemotherapy ± radiotherapy, independent of
age, renal function, BMI, history of or current CVD, treatment with
anti-hormonal therapy and treatment with radiotherapy (Table 2).
In addition, levels of NT-proBNP were significantly increased in BC
survivors compared to controls, as reported previously.14 Levels
of C-reactive protein were similarly increased; however, in multi-
variable analyses, both markers were not associated with LVEF in
survivors treated with chemotherapy ± radiotherapy.
Discussion
Results of this study show that BC survivors treated with
chemotherapy have a distinct biomarker profile even more than
10 years following systemic anti-cancer treatment. This suggests
a potential persistent pro-inflammatory state in BC survivors
following treatment with chemotherapy. This pro-inflammatory



















































































.. in BC survivors previously treated with chemotherapy and is
associated with lower LVEF.
This is the first study of its kind studying a large panel of biomark-
ers in late BC survivors. Previous studies investigated biomarkers
during or immediately after treatment.11,25 Particularly troponin
I and T have shown promise in predicting cardiotoxicity following
anti-cancer treatment and suggest that direct cardiac damage might
be a causative factor in early onset cardiotoxicity. However, no dif-
ferences in troponin T levels were observed in the BLOC study
between controls and survivors.26–28 In our study, no significant
differences were found between patients treated with radiotherapy
alone and controls, even after accounting for differences in disease
severity in sensitivity analyses. This may potentially be explained by
the relatively low-dose of radiotherapy received and the modern
machines used in administering radiotherapy, which greatly reduce
the radiation dosages, and the fact that the heart was often out-
side of the radiation beam in the BLOC study.29,30 Furthermore,
survivors previously treated with radiotherapy might have less
advanced BC, which might be an explanation for the differences in
biomarker levels found between patients treated with chemother-
apy/radiotherapy vs. controls and those treated only with radio-
therapy vs. controls.
In contrast, a considerable number of biomarkers were ele-
vated in BC survivors treated with chemotherapy and/or radiother-
apy. These biomarkers were primarily associated with inflamma-
tory pathways and collagen deposition. While no association was
observed between biomarkers and received anthracycline dose,
this might be confounded by the limited overall variation in dose of
anthracyclines received. Scuric et al.13,31 found that BC survivors
treated with chemo- and/or radiotherapy had higher markers of
cellular aging, including more DNA damage and lower telomerase
activity. However, this study only investigated a small number of
markers and the time since follow-up was considerably shorter
compared to the BLOC study. These markers of cellular aging
were associated with higher levels of pro-inflammatory cytokines
including soluble tumour necrosis factor receptor II and objec-
tive measures of cognitive performance. In addition, increases in
pro-inflammatory cytokines during and after anti-cancer treatment
are related to increased fatigue and depression and an important
risk factor for future cardiovascular events.32–34 Pro-inflammatory
and cardiac remodelling markers including growth differentiation
factor 15, galectin-3 and insulin growth factor binding protein
7 are associated with incident cardiovascular events and heart
failure.35–37 Epigenetic imprinting might be responsible for this
pro-inflammatory state – a previous study in BC patients showed
that treatment with chemotherapy left an epigenetic imprint lead-
ing to increased inflammation. Furthermore, this imprint was
associated with symptoms of depression and fatigue long after
treatment.38,39 A separate study performed in 327 individuals
showed that among 37 BC survivors with a median time since treat-
ment of 4 years the extracellular volume was increased compared
to controls, suggesting greater cardiac fibrosis. Our results showed
that pathophysiological processes relating to collagen deposition
were up-regulated. The overall difference in LVEF between sur-
vivors and controls was significant, albeit of a relatively small magni-
tude, as previously reported.14 Furthermore, although we found a
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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significant association between several increased levels of biomark-
ers and a decreased LVEF, the overall effects were relatively small.
In our study, BC survivors previously treated with chemother-
apy showed higher levels of PCSK9. PCSK9 is secreted into
plasma by the liver and binds low-density lipoprotein (LDL)
receptor at the surface of hepatocytes. This leads to less recy-
cling of LDL receptors, reducing LDL-cholesterol clearance.
PCSK9 contributes to increased plaque instability through
pro-inflammatory pathways and active oxidation. In patients
with heart failure, increased levels of PCSK9 are associated
with adverse outcomes.40 Inhibition of PCSK9 stabilizes plaques,
decreased LDL-cholesterol and reduced the risk of cardiovascu-
lar events in patients with established CVD.41,42 Results of our
study suggest that PCSK9 might be a potential bio-target in BC
survivors.
Limitations
This study only included women who survived BC for at least
5 years after diagnosis and are therefore perhaps healthier than
patients at the time of treatment, therefore the effect of the
biomarkers found in this study might be escalated in the direct
phase of treatment. While we performed additional sensitivity
analyses accounting for differences in cancer severity, residual
confounding might have taken place. Biomarker targets found were
not independently confirmed using conventional ELISAs. Receptor
status was not available for survivors in the BLOC study, which
might have confounded our results. Furthermore, the risk for
cardiovascular events might have been over-estimated in the BLOC
study due to non-participation of controls with higher rates of
(previous) cardiovascular events. Lastly, the cross-sectional design
and type of analysis used excludes inference of causality.
Conclusion
Long-term survivors of early BC treated with systemic chemother-
apy and/or radiotherapy show increased levels of biomarkers
related to inflammation and collagen deposition compared to
matched controls. Lastly, many of these biomarkers were associ-
ated with cardiac dysfunction, providing a possible functional link
between a pro-inflammatory state in BC survivors and cardiac dys-
function.
Supplementary Information
Additional supporting information may be found online in the
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